Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 17/20 | 0.69 |
| ▸ | LCK | P06239 | 3/20 | 0.66 |
| ▸ | HTR1D | P28221 | 2/20 | 0.57 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.52 |
| ▸ | CSF1R | P07333 | 1/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.49 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4864546 | 0.88 | MAPK14 (0.78) | MAPK14LCKHTR1DMAPK11CSF1R | |
| SCHEMBL4856455 | 0.85 | MAPK14 (0.74) | MAPK14LCKHTR1DMAPK11CSF1R | |
| SCHEMBL4862347 | 0.84 | MAPK14 (0.69) | MAPK14LCKHTR1DMAPK11CSF1R | |
| SCHEMBL4856439 | 0.82 | MAPK14 (1.00) | MAPK14LCKHTR1DMAPK11 | |
| SCHEMBL4856070 | 0.81 | MAPK14 (0.67) | MAPK14LCKHTR1DMAPK11CSF1R | |
| SCHEMBL6485976 | 0.80 | MAPK14 (1.00) | MAPK14LCKHTR1DCSF1RSLC6A4 | |
| SCHEMBL4865129 | 0.80 | MAPK14 (0.70) | MAPK14LCKHTR1DMAPK11CSF1R | |
| SCHEMBL5471019 | 0.79 | MAPK14 (0.64) | MAPK14LCKHTR1DMAPK11 | |
| SCHEMBL4856639 | 0.78 | MAPK14 (0.77) | MAPK14LCKHTR1DMAPK11CSF1R | |
| SCHEMBL4855098 | 0.78 | MAPK14 (0.77) | MAPK14LCKMAPK11CSF1RMAP2K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7384963-B2 | 2′-Methyl-5-(1,3,4-oxadiazol-2-yl)1, 1′-biphenyl-4-carboxaide derivatives and their use as p38 kinase | GLAXO GROUP LIMITED (GB) | 2008-06-10 | — | — | US | disclosed |
| US-20040266839-A1 | 2'-Methyl-5-(1,3,4-oxadiazol-2-yl)1,1'-biphenyl-4-carboxaide derivatives and their use as p38 kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2004-12-30 | — | — | US | disclosed |
| EP-1435949-A1 | 2' -METHYL-5-(1,3,4-OXADIAZOL-2-YL)-1,1'-BIPHENYL-4-CARBOXAMIDE DERIVATIVES AND THEIR USE AS P38 KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-07-14 | — | — | EP | disclosed |
| WO-2003032986-A1 | 2' -METHYL-5-(1,3,4-OXADIAZOL-2-YL)-1,1'-BIPHENYL-4-CARBOXAMIDE DERIVATIVES AND THEIR USE AS P38 KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2003-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266839-A1 | 2'-Methyl-5-(1,3,4-oxadiazol-2-yl)1,1'-biphenyl-4-carboxaide derivatives and their use as p38 kinase inhibitors | MAPK1, MAPK3, MAPK6 | MAPK14 11/4885LCK 61/4885HTR1D 215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.